Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The First Shall Be Fifth: Salix’s Recombinant C1 Esterase Inhibitor Enters Crowded HAE Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Ruconest must compete with four other HAE therapies approved by FDA since 2008, including a pair of human plasma-derived C1 esterase inhibitors.

You may also be interested in...

Pharming/Santarus’ Recombinant HAE Drug Ruconest Goes Back To FDA

A BLA has been re-submitted to FDA for Ruconest, which is differentiated from other C1 esterase inhibitors by its recombinant structure. But as the fifth drug for the rare hereditary angioedema condition in the U.S. market, commercial expectations are low.

Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr

FDA’s Aug 25 approval of Shire PLC’s Firazyr (icatibant) for acute treatment of attacks of hereditary angioedema, with a label that allows patients to self-administer the drug, puts a convenience advantage up against a first-to-market advantage for the well-established C-1 esterase inhibitors.

Is Europe's HAE Market Big Enough To Sustain All The Competitors?

As more companies of all sizes embrace rare diseases – lured in part by supposed lower regulatory and reimbursement hurdles – some niche markets are beginning to look rather busy.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts